Home > Doctors > Quach Thanh Dung
MSc, MD, Doctor

Quach Thanh Dung

Booking

Overview

Master of Medicine, Doctor Quach Thanh Dung has extensive experience in the examination, diagnosis, and treatment of breast and gynecological cancers, gastrointestinal cancers, and lung cancer.

Before joining the Radiation Oncology Center at Vinmec Times City International Hospital, Dr. Quach Thanh Dung worked in the Oncology Department of the 198 Hospital Cancer Center. After earning her Master’s degree from Hanoi Medical University, Dr. Dung served as the principal investigator in numerous international clinical trials for lung cancer, liver cancer, and esophageal cancer. She has participated in many domestic and international conferences and received advanced oncology training at the University of Pennsylvania, USA. Dr. Dung is also a visiting lecturer at VinUniversity.

Positions

Head of the Department of Medical Oncology

Specialties

Oncology - Radiotherapy, Haematology, Breast pathology

Workplace

Department of Oncology and Hematology - Vinmec Times City International Hospital, Vinmec Cancer Center - Vinmec Times City International General Hospital

Years of experience

16 years

Services

Breast and gynecological cancer
Gastroenterological cancer
Head and neck cancer
Non – Hodgkin Lymphoma
Hodgkin Lymphoma

2004 – 2010: Hai Phong medical school major

 

Hands-on training in ultrasound and microwave ablation therapy for liver cancer at Cho Ray Hospital.

 

September 2016 – September 2018: Master’s degree in Oncology at Hanoi Medical University.

 

September 2021 – January 2022: Advanced oncology training at the University of Pennsylvania.

From 2011 to 2016: Medical Oncologist at the Cancer Center, 198 Hospital.

 

From May 2020 to December 2021: Head of the Inpatient Oncology and Hematology Unit, Vinmec Times City International Hospital.

 

From February 2025 to present: Head of the Department of Medical Oncology and Hematology.

Vietnam Cancer Society

 

Armed Forces Cancer Association

 

European Society for Medical Oncology (ESMO).

  • Treatment of hepatocellular carcinoma by microwave ablation: Microwave ablation for hepatocellular carcinoma treatment
  • Efficacy of Pembrolizumab in the treatment of various malignancies in Vietnam: Evaluating the efficacy of Pembrolizumab across multiple malignancies in Vietnam
  • Phase II trial combining Osimertinib and Savolitinib in patients with metastatic EGFR-mutant, MET-positive non-small cell lung cancer (NSCLC) progressing on Osimertinib (SavannH trial): Principal Investigator
  • Successful treatment of T/NK-cell lymphoma with immunotherapy: Co-author
  • Efficacy of autologous immunotherapy across various malignancies: Co-author
  • Phase II, multicenter, double-blind, randomized study comparing Savolitinib plus Osimertinib versus Savolitinib plus placebo in patients with locally advanced or metastatic EGFR+/MET+ non-small cell lung cancer who have progressed on Osimertinib (CoC study): Principal Investigator
  • Phase III, randomized, open-label, sponsor-blind, multicenter trial of Durvalumab plus Tremelimumab ± Lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE alone in patients with locoregional hepatocellular carcinoma (EMERALD-3): Principal Investigator
  • Durvalumab versus placebo in combination with definitive chemoradiotherapy in patients with early-stage esophageal cancer (KUNLUN trial): Principal Investigator
Get Free Quote